NCT06065891 (PALN) is a NA clinical trial of PALN resection in Pancreas Cancer, sponsored by Jon Unosson.

Who is sponsoring NCT06065891?

NCT06065891 is sponsored by Jon Unosson.

What drugs are being tested in NCT06065891?

Interventions in NCT06065891: PALN resection.

What condition does NCT06065891 study?

NCT06065891 studies Pancreas Cancer, Pancreas Adenocarcinoma, Lymph Node Metastasis.

Is NCT06065891 still recruiting?

NCT06065891 is currently recruiting now. Last updated 4 October 2023.

Last reviewed 2023-10-04 · How we verify

NCT06065891: PALN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

Recruiting now NA Last updated 4 October 2023

What this trial tests

NA trial testing PALN resection in Pancreas Cancer in 300 participants. Currently enrolling.

Timeline

5 September 2023

Primary endpoint
5 September 2026

5 September 2028

Quick facts

Lead sponsor	Jon Unosson
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	5 September 2023
Primary completion	5 September 2026
Estimated completion	5 September 2028
Sites	6 locations across Denmark, Sweden

Drugs / interventions tested

PALN resection

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →
Pancreas Adenocarcinoma — all drugs for Pancreas Adenocarcinoma →
Lymph Node Metastasis — all drugs for Lymph Node Metastasis →

Sponsor

Jon Unosson

Who can join

18 and older, any sex, with Pancreas Cancer or Pancreas Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned. The aim of this study is to define the incidence and clinical consequences of PALN metastasis in patients submitted to a tentative curative resection for carcinoma of the head of the pancreas by systematically resecting paraaortic lymph nodes. Primary outcome 1\) To determine incidence of PALN metastasis in patients submitted to a tentative curative resection Secondary outcomes 1. To determine prognosis of patients with PALN metastasis after a curative resection 2. To determine incidence of metastasis in reginal lymph nodes in patients submitted to a tentative curative resection. 3. To determine prognosis of patients with metastasis in regional lymph nodes in patients submitted to a tentative curative resection. 4. To address the question of how to optimize the frozen section analyses of PALN as related to the final pathology report. 300 patients are planned to be included in the trial.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.
Wu Y, Shang J, Zhang X, Li N. · · 2024 · cited 5× · PMID 39702277 · DOI 10.1186/s12951-024-02940-4

Verify or expand the search:

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Jon Unosson trials

Trials by the same sponsor.

NCT05744219 — Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06065891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jon Unosson
Last refreshed: 4 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06065891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing